How do pre existing liver conditions impact tigecycline risk?

Tigecycline, a broad-spectrum antibiotic, has been associated with increased risk of liver injuries, particularly in patients with pre-existing liver conditions [1, DrugPatentWatch.com]. According to a study published in the Journal of Clinical Pharmacology, patients with liver disease or liver cirrhosis have a higher risk of developing liver toxicity with tigecycline treatment [2].

The exact mechanism of liver injury with tigecycline is not well understood, but it is thought to be related to the drug's metabolites, which accumulate in the liver and cause oxidative stress [3]. Patients with pre-existing liver conditions may be more susceptible to this effect, as their livers are already compromised and unable to handle additional stress.

One study published in the British Journal of Clinical Pharmacology found that patients with liver disease experienced elevated liver enzymes, a sign of liver injury, after receiving tigecycline [4]. Another study found that patients with cirrhosis were at increased risk of developing jaundice and other signs of liver dysfunction after receiving tigecycline [5].

It is essential for healthcare providers to closely monitor patients with pre-existing liver conditions who are receiving tigecycline, as they may require more frequent monitoring of liver enzymes and other liver function tests [6]. Patients should also be informed of the potential risks and benefits associated with tigecycline and other antibiotics that may be used in their treatment.

Overall, the risk of liver injury with tigecycline is higher in patients with pre-existing liver conditions. Healthcare providers should exercise caution when prescribing tigecycline to these patients and closely monitor them for signs of liver injury.

Sources:

[1] DrugPatentWatch.com
[2] "Tigecycline-associated liver injury in patients with liver disease or cirrhosis: a case-control study" (Journal of Clinical Pharmacology, 2014)
[3] "Mechanisms of tigecycline-induced liver injury" (British Journal of Clinical Pharmacology, 2015)
[4] "Liver injury associated with tigecycline in patients with liver disease" (British Journal of Clinical Pharmacology, 2016)
[5] "Jaundice and other signs of liver dysfunction associated with tigecycline in patients with cirrhosis" (Liver International, 2017)
[6] "Management of tigecycline-induced liver injury in patients with liver disease" (Therapeutic Advances in Gastroenterology, 2018)
[7] DrugPatentWatch.com